Tolmar, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$8.5M
Doctors Paid
9,082
Transactions
24,484
2024 Total
$2.5M
Payment Breakdown by Category
Research$7.8M (91.1%)
Food & Beverage$410,547 (4.8%)
Consulting$58,568 (0.7%)
Travel$13,078 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7.8M | 2,872 | 91.1% |
| Food and Beverage | $410,547 | 20,366 | 4.8% |
| Honoraria | $241,518 | 115 | 2.8% |
| Consulting Fee | $58,568 | 24 | 0.7% |
| Space rental or facility fees (teaching hospital only) | $25,500 | 3 | 0.3% |
| Travel and Lodging | $13,078 | 20 | 0.2% |
| Education | $7,637 | 1,084 | 0.1% |
Payments by Type
Research
$7.8M
2,872 transactions
General
$756,847
21,612 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| TOL3010B | $1.9M | 0 | 381 |
| TOL2506A | $1.6M | 5 | 662 |
| Talconex (TOLMAR Calcipotriene Hydrate and Betamthason Dipropionate Topical Suspension 0.005%/0.064%) in the treatment of Scalp Psoriasis | $1.4M | 0 | 241 |
| A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer | $873,387 | 0 | 1,065 |
| A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO for 12 Months | $529,422 | 0 | 131 |
| Open-label, Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study | $505,584 | 0 | 162 |
| TOL2581A | $170,193 | 3 | 31 |
| A Phase 3, Single Arm, OpenLabel Study Evaluating Ovarian Suppression Following ThreeMonth Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with HormoneReceptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)Negative Breast Cancer | $164,323 | 0 | 88 |
| TOL2707A | $150,335 | 0 | 5 |
| TOL2708C | $118,140 | 0 | 20 |
| A Pivotal Pharmacokinetic Bioequivalence Study Comparing Genericto Reference Liposome-Encapsulated Doxorubicin Hydrochloride inSubjects with Epithelial Ovarian Carcinoma Who Have FailedPlatinum-Based Chemotherapy | $115,045 | 0 | 14 |
| TOL2581A-CPP | $100,953 | 3 | 35 |
| TOL2506A-EXT | $67,270 | 0 | 25 |
| TOL2649G | $67,179 | 0 | 9 |
| Calcipotriene Ointment, 0.005% and Plaque Psoriasis | $12,450 | 0 | 1 |
| A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-ReceptorPositive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer | $8,426 | 1 | 2 |
Payments by Medical Specialty
Top Paid Doctors — Page 3
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Dr. Anthony Heaney, M.d, M.D | Endocrinology, Diabetes & Metabolism | Los Angeles, CA | $603.29 | $0 |
| Dr. Joshua Yang, Md, MD | Pediatric Endocrinology | Orlando, FL | $546.29 | $0 |
| Wenyu Huang, M.d., Ph.d, M.D., PH.D | Internal Medicine | Chicago, IL | $535.00 | $0 |
| Dr. Aniket Chakrabarti, M.d, M.D | Internal Medicine | Pembroke, MA | $525.51 | $0 |
| Ms. Kathryn Springfield, Pa-C, PA-C | Physician Assistant | Plano, TX | $518.90 | $0 |
| Amy Burton, M.d, M.D | Pediatric Endocrinology | Plano, TX | $512.98 | $0 |
| Antonio Bianco, M.d, M.D | Internal Medicine | Chicago, IL | $500.00 | $0 |
| Dr. Peter Lewitt, M.d, M.D | Neurology | West Bloomfield, MI | $500.00 | $0 |
| Dr. Kamal Nagpal, Md, MD | Student in an Organized Health Care Education/Training Program | Glendale, AZ | $486.32 | $0 |
| Frank Lafazia, D.o, D.O | Family Medicine | West Warwick, RI | $441.42 | $0 |
| Dr. Mark Saslawsky, M.d, M.D | Urology | Memphis, TN | $430.72 | $0 |
| Toni Kim, Md, MD | Pediatric Endocrinology | Sandy Springs, GA | $425.47 | $0 |
| Joshua Calvert, Md,Mph, MD,MPH | Urology | Nashville, TN | $417.38 | $0 |
| Mr. Tzvetan Tzvetanov, M.d, M.D | Internal Medicine | North Andover, MA | $382.57 | $0 |
| Lawrence Gervasi, Md, MD | Urology | Middleburg Heights, OH | $380.99 | $0 |
| Henry Vanpala, Np, NP | Adult Health | Raleigh, NC | $379.25 | $0 |
| Dr. Ana Paez, Md, MD | Pediatric Endocrinology | Corpus Christi, TX | $368.72 | $0 |
| Shari Tomasetti, Pa, PA | Physician Assistant | Boston, MA | $367.58 | $0 |
| Govardhanan Nagaiah, Md, MD | Hematology & Oncology | Goodyear, AZ | $363.20 | $0 |
| Karen Brann, Apn, APN | Emergency | Chicago Ridge, IL | $360.59 | $0 |
| Mario Carcamo, Md, MD | Pediatric Endocrinology | Riverside, CA | $358.83 | $0 |
| Dr. Phillip Ginsberg, D.o, D.O | Specialist | Philadelphia, PA | $358.08 | $0 |
| Mr. Kevin Lai, Pa-C, PA-C | Physician Assistant | Boston, MA | $357.17 | $0 |
| Shilpa Mehta, M.d, M.D | Pediatric Endocrinology | Brooklyn, NY | $354.83 | $0 |
| Rola Saad, Md, MD | Pediatrics | Phoenix, AZ | $352.76 | $0 |
Ad
Top Products
- Leuprolide Acetate $1.7M
- Talconex (TOLMAR Calcipotriene Hydrate and Betamthason Dipropionate Topical Suspension 0.005%/0.064% $1.4M
Associated Products (13)
- Leuprolide Acetate $1.7M
- Talconex (TOLMAR Calcipotriene Hydrate and Betamthason Dipropionate Topical Suspension 0.005%/0.064% $1.4M
- JATENZO $1.2M
- TOL3010B $1.0M
- Paliperidone Palmitate $876,180
- TOL2707A $150,335
- TOL2581A $119,766
- Doxorubicin Hydrochloride Liposome Injection- Epithelial Ovarian Carcinoma $115,045
- TOL2708C $111,095
- Eligard 45mg and CPP $100,953
- TOL2649G $67,179
- Eligard $54,537
- Calcipotriene Ointment, 0.005% and Plaque Psoriasis $12,450
Payment Categories
- Food & Beverage $410,547
- Consulting $58,568
- Travel & Lodging $13,078
- Research $7.8M
About Tolmar, Inc.
Tolmar, Inc. has made $8.5M in payments to 9,082 healthcare providers, recorded across 24,484 transactions in the CMS Open Payments database. In 2024, the company paid $2.5M. The top product by payment volume is Leuprolide Acetate ($1.7M).
Payments were distributed across 146 medical specialties. The top specialty by payment amount is Hematology & Oncology ($209,143 to 153 doctors).
Payment categories include: Food & Beverage ($410,547), Consulting ($58,568), Research ($7.8M), Travel & Lodging ($13,078).
Tolmar, Inc. is associated with 13 products in the CMS Open Payments database, including Leuprolide Acetate, Talconex (TOLMAR Calcipotriene Hydrate and Betamthason Dipropionate Topical Suspension 0.005%/0.064%, and JATENZO.